tbuckley/cabot-search huggingface dataset:
Associations Between Prenatal Cannabis Exposure and Childhood Outcomes
Authors: Sarah E. Paul, Alexander S. Hatoum, Jeremy D. Fine, Emma C. Johnson, Isabella Hansen, Nicole R. Karcher, Allison L. Moreau, Erin Bondy, Yueyue Qu, Ebony B. Carter, Cynthia E. Rogers, Arpana Agrawal, Deanna M. Barch, Ryan Bogdan
Journal: JAMA Psychiatry (2020)

In light of increasing cannabis use among pregnant women, the US Surgeon General recently issued an advisory against the use of marijuana during pregnancy.To evaluate whether cannabis use during pregnancy is associated with adverse outcomes among offspring.In this cross-sectional study, data were obtained from the baseline session of the ongoing longitudinal Adolescent Brain and Cognitive Development Study, which recruited 11 875 children aged 9 to 11 years, as well as a parent or caregiver, from 22 sites across the United States between June 1, 2016, and October 15, 2018.Prenatal cannabis exposure prior to and after maternal knowledge of pregnancy.Symptoms of psychopathology in children (ie, psychotic-like experiences [PLEs] and internalizing, externalizing, attention, thought, and social problems), cognition, sleep, birth weight, gestational age at birth, body mass index, and brain structure (ie, total intracranial volume, white matter volume, and gray matter volume). Covariates included familial (eg, income and familial psychopathology), pregnancy (eg, prenatal exposure to alcohol and tobacco), and child (eg, substance use) variables.Among 11 489 children (5997 boys [52.2%]; mean [SD] age, 9.9 [0.6] years) with nonmissing prenatal cannabis exposure data, 655 (5.7%) were exposed to cannabis prenatally. Relative to no exposure, cannabis exposure only before (413 [3.6%]) and after (242 [2.1%]) maternal knowledge of pregnancy were associated with greater offspring psychopathology characteristics (ie, PLEs and internalizing, externalizing, attention, thought and, social problems), sleep problems, and body mass index, as well as lower cognition and gray matter volume (all |β| > 0.02; all false discovery rate [FDR]-corrected P < .03). Only exposure after knowledge of pregnancy was associated with lower birth weight as well as total intracranial volume and white matter volumes relative to no exposure and exposure only before knowledge (all |β| > 0.02; all FDR-corrected P < .04). When including potentially confounding covariates, exposure after maternal knowledge of pregnancy remained associated with greater PLEs and externalizing, attention, thought, and social problems (all β > 0.02; FDR-corrected P < .02). Exposure only prior to maternal knowledge of pregnancy did not differ from no exposure on any outcomes when considering potentially confounding variables (all |β| < 0.02; FDR-corrected P > .70).This study suggests that prenatal cannabis exposure and its correlated factors are associated with greater risk for psychopathology during middle childhood. Cannabis use during pregnancy should be discouraged.
1747P Chemotherapy prescriptions and emergency medical care utilization by patients in neo/adjuvant breast cancer treatment during COVID-19 pandemic: Patterns in a Brazilian University Hospital
Authors: F.F. Pimentel, J.M.C. Borba, T.C.G.F. Rodrigues, K.P.I. Peruchi, H.H.A. Carrara, J.M. de Andrade, F.J. Candido dos Reis
Journal: Annals of Oncology (2020)
1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
Authors: A. Prelaj, A. Bottiglieri, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, S. Manglaviti, M. Occhipinti, A. Labianca, R. Gallucci, G. Molino, N. Zilembo, F.G. Greco, V. Torri, M.C. Garassino
Journal: Annals of Oncology (2020)
1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis
Authors: N.A. Waser, A. Adam, B. Schweikert, L. Vo, M. McKenna, M. Breckenridge, J.R. Penrod, S. Goring
Journal: Annals of Oncology (2020)
1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma
Authors: J.M. Kirkwood, R. Dummer, A. Hauschild, M. Santinami, V. Atkinson, V. Chiarion Sileni, J. Larkin, M.S. Nyakas, A.M. Haydon, C. Dutriaux, J. Schachter, C. Robert, L. Mortier, H. Banerjee, T. Haas, M. Tan, M. Lau, D. Schadendorf, G.V. Long, M. Mandala'
Journal: Annals of Oncology (2020)
1637P Impact of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and updated meta-analysis
Authors: A. Rizzo, M. Nannini, A. Astolfi, V. Indio, P. De Iaco, A.M. Perrone, A. De Leo, A.D. Ricci, M.C. Nigro, R. Pagani, V. Di Scioscio, M.A. Pantaleo
Journal: Annals of Oncology (2020)
905P Outcomes of fludarabine, melphalan and low dose total body irradiation as a reduced intensity regimen in allogeneic peripheral blood stem cell transplantation
Authors: D. Modi, J. Chi, S. Kim, L. Ayash, A. Alavi, A. Kin, V. Ratanatharathorn, A. Deol, J. Uberti
Journal: Annals of Oncology (2020)
183P Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor negative (HER2-) early breast cancer
Authors: A. Diana, F. Iovino, F. Carlino, A. Perrone, C. Trovato, I. Vassallo, G. Antoniol, M. Caraglia, R. Franco, F. Ciardiello, M. Orditura
Journal: Annals of Oncology (2020)
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Authors: Zerui Wang, Katelyn Becker, Vincenzo Donadio, Sandra Siedlak, Jue Yuan, Masih Rezaee, Alex Incensi, Anastasia Kuzkina, Christina D. Orrú, Curtis Tatsuoka, Rocco Liguori, Steven A. Gunzler, Byron Caughey, Maria E. Jimenez-Capdeville, Xiongwei Zhu, Kathrin Doppler, Li Cui, Shu G. Chen, Jiyan Ma, Wen-Quan Zou
Journal: JAMA Neurology (2020)

Deposition of the pathological α-synuclein (αSynP) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays can sensitively detect skin biomarkers for PD and non-PD synucleinopathies remains unknown.
Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAX‐AHF</scp>‐2 study
Authors: Siting Feng, Satit Janwanishstaporn, John R. Teerlink, Marco Metra, Gad Cotter, Beth Davison, G. Michael Felker, Gerasimos Filippatos, Peter Pang, Piotr Ponikowski, Iziah E. Sama, Adriaan A. Voors, Barry Greenberg
Journal: European Journal of Heart Failure (2020)
1547P Project Survival®: High-fidelity longitudinal phenotypic and multi-omic characterization of pancreatic ductal adenocarcinoma (PDAC) for biomarker discovery
Authors: A.J. Moser, M.A. Kiebish, E.M. Grund, C.L. DeCicco, N.M. Chand, K. Schawkat, G.L. Perez-Melara, G.M. Miller, L.O. Rodrigues, E. Granger, R. Sarangarajan, N.R. Narain
Journal: Annals of Oncology (2020)
Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review
Authors: Bartolome R. Celli, Julie A. Anderson, Nicholas J. Cowans, Courtney Crim, Benjamin F. Hartley, Fernando J. Martinez, Andrea N. Morris, Holly Quasny, Julie Yates, Jørgen Vestbo, Peter M. A. Calverley
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Whether pharmacological therapy alters decline in FEV1 in chronic obstructive pulmonary disease remains controversial. Because pharmacotherapy improves health status, exacerbation rate, and symptoms, it may be unethical to complete placebo-controlled long-term studies aimed at modifying FEV1 decline.Objectives: We conducted a systematic review of placebo-controlled pharmacological trials lasting ≥1 year to address the question of whether therapy alters FEV1 decline.Methods: A literature search for randomized trials that included repeated spirometry with at least one active and one placebo arm was conducted. Articles were excluded if study duration was <1 year, <3 spirometric measurements, or <100 subjects per arm. Study design was assessed using the Jadad score. To combine studies and find the estimated effect, we used random effects methodology to account for both within-study and between-study variation.Measurements and Main Results: There were 33,051 patients in the analysis (active component, n = 21,941; placebo, n = 11,110 in nine studies). The active treatment arms demonstrated a 5.0 ml/yr reduction (95% confidence interval, 0.8–9.1 ml/yr; P < 0.001) in the rate of FEV1 decline compared with the placebo arms. The relative FEV1 differences between active and placebo arms were within the range of differences reported for health status and for the exacerbation rate in the same studies.Conclusions: In chronic obstructive pulmonary disease, pharmacotherapy ameliorates rate of lung function decline. The relative benefit observed is within the range of those reported for health status and exacerbations in the same studies. Guidelines should be adjusted according to these findings.
Removal of embedded partially covered self-expandable metal stents in endoscopic ultrasound-guided hepaticogastrostomy
Authors: Nozomi Okuno, Kazuo Hara, Shin Haba, Takamichi Kuwahara, Hiroki Koda, Akira Miyano, Moaz Elshair
Journal: Endoscopy (2020)

Endoscopic ultrasound (EUS)-guided hepaticogastrostomy (HGS) is a widely used procedure. Despite high success rates, reintervention is sometimes needed and can be complicated. Partially covered self-expandable metal stents (PCSEMS) often cause hyperplasia, which can impede stent removal [1] [2]. We used to use PCSEMS, but now use 6-mm fully covered self-expandable stents (FCSEMS) for ease of reintervention [3].
590P A double-blind, randomized, parallel group study to demonstrate the equivalent pharmacokinetic properties of a single intravenous dose HD201, a trastuzumab biosimilar candidate, versus EU trastuzumab and US trastuzumab
Authors: M. Demarchi, P. Coliat, J. Chung Shii Hii, P. Feyaerts, F. Ang, J. Litha, F. Deforce, A. Detappe, M.P. Derde, M. Kim, L. Park, P. Xavier
Journal: Annals of Oncology (2020)
1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium
Authors: C. Palmieri, L. Turtle, A. Docherty, E. Harrison, T. Drake, B. Greenhalf, P.J. Openshaw, J.K. Baillie, M.G. Semple
Journal: Annals of Oncology (2020)
893MO An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Authors: Y. Xie, L. Mi, W. Zheng, L. Ping, N. Lin, M. Tu, C. Zhang, Z. Ying, W. Liu, L. Deng, M. Wu, X. Wang, J. Zhu, Y. Song
Journal: Annals of Oncology (2020)
1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Authors: R. McDermott, C.M. van Tilburg, A.F. Farago, S. Kummar, D.S.W. Tan, C.M. Albert, J. Berlin, U.N. Lassen, F. Doz, B. Geoerger, L. Mascarenhas, N. Federman, J.A. Reeves, L. Dima, N. Brega, E. De La Cuesta, T.W. Laetsch, D.S. Hong, A. Drilon
Journal: Annals of Oncology (2020)
611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)
Authors: N. James, H. Rush, N. Clarke, G. Attard, A. Cook, D. Dearnaley, S. Gillessen, A. Hoyle, R. Jones, R. Millman, A. Birtle, S. Chowdhury, J. Gale, Z. Malik, J. O'Sullivan, C. Pezaro, D. Sheehan, J. Tanguay, M.K. Parmar, M.R. Sydes
Journal: Annals of Oncology (2020)

Abiraterone acetate plus prednisolone previously showed a clear survival advantage in men starting long-term hormone therapy for prostate cancer in STAMPEDE, a randomized controlled trial using a multi-arm multi-stage platform design. STAMPEDE included a wide range of men with M1 or M0 disease. The LATITUDE trial, in patients with high-burden M1 disease only, reported a similar magnitude of effect to the comparable subset of STAMPEDE pts. We report long-term outcomes in the M1 subset of pts in STAMPEDE. All patients received androgen deprivation therapy (ADT). Stratified randomization allocated pts 1:1 to ADT alone or adding daily abiraterone acetate 1000mg + prednisolone 5mg (SOC+AAP) continued until PSA, radiological & clinical progression. The primary outcome measure was death from any cause. The data freeze for this long-term analysis was planned for 3yr after the primary survival results when a meaningful increase in data was anticipated. Analyses used Cox proportional hazards & flexible parametric models, adjusted for baseline stratification factors. Of 1,917 pts contemporaneously randomized to these groups (Nov-2011 to Jan-2014), 1,003 (52%) had M1 disease. The M1 groups were balanced: median age 67yr; 48% high-burden, 44% low-burden, 8% burden not assessable; 94% newly-diagnosed; median PSA 97ng/ml. Median follow-up had increased from 3.5yr to 6.1yr & number of ADT-only deaths increased by 50%, from 218 previously to 329. With 244 ADT+AAP deaths, the adjusted HR=0·60 (95%CI 0·50—0·71; p=0.31x10-9) favouring ADT+AAP, with 5-yr survival improved from 41% ADT-only to 60% ADT+AAP. The relative effect of abiraterone was similar in low-burden (HR=0·55; 95%CI 0·41—0·76) and high-burden (HR=0·54; 95%CI 0·43—0·69) patients. Median time on ADT+AAP was 2.4yr, with a current maximum of 8.1yr. Toxicity at 4yr post-randomisation was similar, with 16% of patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of M1 prostate cancer patients was achieved with ADT + abiraterone acetate + prednisolone, irrespective of burden of disease.
374P Temozolamide (TMZ) rechallenge at standard or metronomic dose versus other treatments in patients (pts) with high grade glioma with TMZ free-interval (TFI) longer than 3 months (mo)
Authors: A. Garcia-Alvarez, N. Saoudi, M. Gonzalez, F. Ruiz-Pace, E. Martinez Saez, M.J. Lostes Bardaji, J.D.D. Assaf Pastrana, F. Martinez-Ricarte, X. Maldonado, R. Dienstmann, J. Carles, M. Vieito Villar
Journal: Annals of Oncology (2020)
417P Lymph node (LN) retrieval as a high-risk factor in stage II and III colon cancer
Authors: Y.T. Kim, H.S. Kim, S.J. Shin, S-H. Beom, N.K. Kim, K.Y. Lee, B.S. Min, H. Hur, M.S. Cho, Y.D. Han, S.Y. Yang, W.S. Koom, J.S. Chang, T.I. Kim, J.H. Cheon, S.J. Park, J.J. Park, N.E. Seo, J.S. Lim, J.B. Ahn
Journal: Annals of Oncology (2020)
719P Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Authors: C-H. Lee, Y. Adachi, H. Ikezawa, S.D. Li, Y. Funahashi, Y. Minoshima, P. Kubiak, R. Perini, M. Ren, A.D. Smith, R.J. Motzer
Journal: Annals of Oncology (2020)
416P A novel prognostic tool based on lymphocyte ratios in patients with stage III colon cancer
Authors: D. Basile, M. Polano, S. Buriolla, C. Gallois, F. Cortiula, C. Corvaja, M. De Scordilli, A. Michelotti, G. Pelizzari, E. Ongaro, M. Casagrande, L. Foltran, G. Toffoli, N. Pella, A. Buonadonna, A. Zaanan, G. Fasola, G. Aprile, J. Taieb, F. Puglisi
Journal: Annals of Oncology (2020)
1109P Chinese subgroup results from an open-label, phase IIa study of dabrafenib plus trametinib in Asian patients with advanced BRAF V600-mutant melanoma (NCT02083354)
Authors: L. Mao, X. Wen, None Y. xu, L. Si, X. Zhang, Y. Fan, J. Guo
Journal: Annals of Oncology (2020)
1440P Safety and efficacy of FLOT regimen neoadjuvant treatment in Polish population: Interim analysis of prospective biomarker study
Authors: K. Marcisz-Grzanka, M. Winiarek, M. Mydłowska, A. Kolasińska-Ćwikła, T. Olesiński, R. Samsel, M. Jóźwiak, L. Wyrwicz
Journal: Annals of Oncology (2020)
405MO Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases
Authors: F. Loupakis, M. Derouazi, S. Murgioni, M.D. Rizzato, S. Sharma, D. Renner, S. Shchegrova, H. Sethi, B. Zimmermann, A. Aleshin, M. Schirripa, G. Munari, A.P. Dei Tos, S. Lonardi, M. Fassan
Journal: Annals of Oncology (2020)
2009P Gastric cancer in BRCA1 germ-line mutation carriers: Results of endoscopic screening and molecular analysis of tumour tissues
Authors: A. Sokolenko, A. Avanesyan, A.O. Ivantsov, T. Sokolova, M. Kleshchov, O. Tkachenko, A. Scherbakov, E. Imyanitov
Journal: Annals of Oncology (2020)
CN44 Thrombosis in cancer patients related to central venous catheter
Authors: A. Benito-Yagüe, C. Garzón-Serrano, I. de la Haba, E. Coma, R. Comabella, M. Rodríguez, R. Mestre, P. Fernández-Ortega
Journal: Annals of Oncology (2020)
254P Different patterns of distant recurrence depending on the expression of hormone receptor in breast cancer patients with pathological complete response to neoadjuvant chemotherapy
Authors: J. Ponce, A. Rodriguez-Lescure, S. Delgado, H. Ballester, M. Pastor-Valero, Y.G. Montoyo-Pujol, M. Garcia-Escolano, T. Martín, G. Peiró, F. Aranda, M. Niveiro, M. Reche, I. Lozano, B. Massuti Sureda
Journal: Annals of Oncology (2020)
Control of Systemic Iron Homeostasis by the 3’ Iron‐Responsive Element of Divalent Metal Transporter 1 in Mice
Authors: Elisabeth Tybl, Hiromi Gunshin, Sanjay Gupta, Tomasa Barrientos, Michael Bonadonna, Ferran Celma Nos, Gael Palais, Zoubida Karim, Mayka Sanchez, Nancy C. Andrews, Bruno Galy
Journal: HemaSphere (2020)

Supplemental Digital Content is available in the text
1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
Authors: H. Hayashi, M. Okada, T. Kijima, K. Aoe, T. Kato, N. Fujimoto, K. Nakagawa, Y. Takeda, T. Hida, K. Kanai, J. Hirano, Y. Namba, Y. Ohe
Journal: Annals of Oncology (2020)
1185P [18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia
Authors: M. Rinzivillo, D. Prosperi, F. Mazzuca, L. Magi, E. Iannicelli, E. Pilozzi, G. Franchi, G. Gentiloni Silveri, A. Laghi, B. Annibale, A. Signore, F. Panzuto
Journal: Annals of Oncology (2020)
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone
Authors: Sima Khazaei, Nicolas De Jay, Shriya Deshmukh, Liam D. Hendrikse, Wajih Jawhar, Carol C.L. Chen, Leonie G. Mikael, Damien Faury, Dylan M. Marchione, Joel Lanoix, Éric Bonneil, Takeaki Ishii, Siddhant U. Jain, Kateryna Rossokhata, Tianna S. Sihota, Robert Eveleigh, Véronique Lisi, Ashot S. Harutyunyan, Sungmi Jung, Jason Karamchandani, Brendan C. Dickson, Robert Turcotte, Jay S. Wunder, Pierre Thibault, Peter W. Lewis, Benjamin A. Garcia, Stephen C. Mack, Michael D. Taylor, Livia Garzia, Claudia L. Kleinman, Nada Jabado
Journal: Cancer Discovery (2020)

Abstract Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation. By profiling the epigenome, transcriptome, and secreted proteome of patient samples and tumor-derived cells CRISPR–Cas9-edited for H3.3 G34W, we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the repressive H3K27me3 mark from intergenic to genic regions, beyond areas of H3.3 deposition. This promotes redistribution of other chromatin marks and aberrant transcription, altering cell fate in mesenchymal progenitors and hindering differentiation. Single-cell transcriptomics reveals that H3.3 G34W stromal cells recapitulate a neoplastic trajectory from a SPP1+ osteoblast-like progenitor population toward an ACTA2+ myofibroblast-like population, which secretes extracellular matrix ligands predicted to recruit and activate osteoclasts. Our findings suggest that H3.3 G34W leads to GCT by sustaining a transformed state in osteoblast-like progenitors, which promotes neoplastic growth, pathologic recruitment of giant osteoclasts, and bone destruction. Significance: This study shows that H3.3 G34W drives GCT tumorigenesis through aberrant epigenetic remodeling, altering differentiation trajectories in mesenchymal progenitors. H3.3 G34W promotes in neoplastic stromal cells an osteoblast-like progenitor state that enables undue interactions with the tumor microenvironment, driving GCT pathogenesis. These epigenetic changes may be amenable to therapeutic targeting in GCT. See related commentary by Licht, p. 1794. This article is highlighted in the In This Issue feature, p. 1775
1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib
Authors: R. Dziadziuszko, F. André, W.-K. Yip, X. Wu, J. Skoletsky, R. Woodhouse, T. Hung, T.R. Wilson, T. Riehl, L. Dennis, M. Li
Journal: Annals of Oncology (2020)
425P Statins increase pathological response in locally advanced rectal cancer (LARC) treated with chemo-radiation (CRT): A multicentric experience
Authors: C. Santini, F. Caputo, A. Casadei Gardini, K. Cerma, C. Bardasi, A. Passardi, I. Garajovà, I.G. Rapposelli, E. Lattanzi, A. Spallanzani, L. Reggiani Bonetti, M. Piccoli, B. Meduri, R. Gelmini, A. Pecchi, S. Benatti, M. Dominici, G. Luppi, F. Gelsomino
Journal: Annals of Oncology (2020)
PPARα mediates night neon light-induced weight gain: role of lipid homeostasis
Authors: Yishuang Luo, Julin Yang, Jinyu Kang, Kuihao Chen, Xiaofeng Jin, Frank J Gonzalez, Aiming Liu
Journal: Theranostics (2020)

Rationale: Light pollution leads to high risk of obesity but the underlying mechanism is not known except for the influence of altered circadian rhythm. Peroxisome proliferator-activated receptor α (PPARα) regulates lipid metabolism, but its role in circadian-related obesity is not clear. Methods: Wild-type (WT) and Ppara-null (KO) mice on a high-fat diet (HFD) were treated with neon light at night for 6 weeks. Body weights were recorded and diet consumption measured. The hypothalamus, liver, adipose and serum were collected for mechanism experimentation. Results: WT mice on a HFD and exposed to night neon light gained about 19% body weight more than the WT control mice without light exposure and KO control mice on a HFD and exposed to night neon light. The increase in adipose tissue weight and adipocyte size led to the differences in body weights. Biochemical analysis suggested increased hepatic lipid accumulated and increased transport of lipid from the liver to peripheral tissues in the WT mice that gained weight under neon light exposure. Unlike KO mice, the expression of genes involved in lipid metabolism and the circadian factor circadian locomotor output cycles kaput (CLOCK) in both liver and adipose tissues were elevated in WT mice under neon light exposure. Conclusions: PPARα mediated weight gain of HFD-treated mice exposed to night neon light. More lipids were synthesized in the liver and transported to peripheral tissue leading to adaptive metabolism and lipid deposition in the adipose tissue. These data revealed an important mechanism of obesity induced by artificial light pollution where PPARα was implicated.
842P Carboplatin-induced thrombocytopenia in ovarian cancer: A focus on predictive factors
Authors: R. Mazzeo, M. Bartoletti, M. de Scordilli, M. Alberti, A. Michelotti, C. Lisanti, A. Parnofiello, E. Bertoli, S. Buriolla, G. Pelizzari, F. Cortiula, D. Basile, S. Gagno, S. Scalone, M.S. Nicoloso, S. Corsetti, D. Lombardi, L. Gerratana, R. Sorio, F. Puglisi
Journal: Annals of Oncology (2020)
1732P Prognostic indicators for COVID-19 related deaths in patients with cancer
Authors: A. Linehan, D. Cowzer, M. Hennessy, Z. Coyne, O. Fitzpatrick, A. Nolan, L. Judge, N. Cooley, D. O'Doherty, C. Matassa, T. Doyle, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach
Journal: Annals of Oncology (2020)